CHAPTER 87 CHANNELOPATHIES OF MUSCLE (INCLUDING THE MYOTONIC DYSTROPHIES)
Channelopathies are disorders resulting from alterations in function of the ion channels found in cell membranes throughout the body. Disorders such as episodic ataxia types 1 and 2, spinocerebellar ataxia type 6, familial hemiplegic migraine, and benign familial neonatal convulsions are examples of channelopathies affecting the central nervous system. These disorders are outside the scope of this chapter.
Each ion channel type has a different role in sarcolemmal function (Fig. 87-1). Chloride channels are important in stabilizing the membrane potential at the resting level; inward flow of ions through sodium channels induces membrane depolarization and hence action potential; outflow through a voltage-gated subset of potassium channels is involved in the depolarization of the action potential. Calcium channels may be involved in action potential generation or in the regulation of other channel types. Action potential generation in the membrane is coupled to activation of the contractile machinery in the skeletal muscle and to muscle contraction.
Electromyography in patients with myotonia congenita or myotonic dystrophy should demonstrate repetitive generation of muscle cell membrane action potentials (Fig. 87-2) in resting muscle, although the test may be unnecessary in clinically evident cases, particularly of myotonic dystrophy. The myotonic discharges are described as high-frequency repetitive biphasic spikes or positive waves with varying frequency or amplitude. Electromyography in periodic paralysis will be normal between attacks in patients without a myopathy. During an attack, features such as reduced compound muscle action potential amplitude are seen.
NONDYSTROPHIC MYOTONIAS AND PERIODIC PARALYSES
Chloride Channel Disorders (CLCN1)
Epidemiology
Thomsen’s and Becker’s myotonia congenita are allelic disorders due to mutations in the CLCN1 gene, which encodes the voltage-gated chloride channel. Myotonia congenita, Thomsen type, first described in 1876, is an autosomal dominant condition with a prevalence of about 1 : 400,000. Becker’s myotonia congenita, described in 1957, is an autosomal recessive condition, more common than Thomsen’s myotonia, with a prevalence of between 1 : 23,000 and 1 : 50,000.1
Molecular Pathophysiology
CLCN1 mutations are spread throughout the sequence of the gene (Pusch) and are predicted to produce functional changes in the chloride channel protein (CIC-1) with faulty assembly of subunits, impaired ion channel formation, and channel dysfunction (Fig. 87-3). The resulting reduction in chloride ion conductance lowers the threshold for depolarization through sodium channel activation and hence leads to sustained excitability, that is, myotonia.
Treatment
To alleviate the myotonia, mexiletine is currently the first-line agent; it acts as a “membrane-stabilizing” agent, reducing sodium channel activation, but it has no direct effect on chloride channels. Mexilitene should be used with care as toxicity may develop at higher doses. If mexilitene is not effective, it may be worth switching to carbamazepine or phenytoin. Acetazolamide is not beneficial (although it may be in sodium channel myotonias, see later) and—along with other diuretics—may worsen symptoms of myotonia. Many patients believe that treatment for their myotonia is not necessary as they have adapted to their condition and manage their activities without undue disruption. However, even mild untreated myotonia may lead to subsequent muscle weakness.
Care should be taken that depolarizing agents and anticholinesterases are avoided during anesthesia.